Clinical Trial Update: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of two trough ranges of everolimus as adjunctive therapy in tuberous sclerosis complex–associated refractory seizur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberous Sclerosis Complex
• Tuberous Sclerosis Complex-associated Refractory Seizures

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tuberous Sclerosis Complex-associated Refractory Seizures | Phase 3 | Status: COMPLETED | Results posted: 2018-11-07